A Phase 3 interventional study of Lumacaftor and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 20 sites in 2 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-06-20.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 11th largest by enrollment, is one of 7 that started in 2013, is one of 10 in phase 3, and was the 8th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →
lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 7 started in 2013.
This study's enrollment of 62 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 66 across the 20 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 1 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 69th largest by enrollment of the 116 interventional ones that give a count, is one of 11 that started in 2013, is one of 62 in phase 3, and was the 28th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, 2-part (Part A and Part B), open-label, multicenter study to evaluate the pharmacokinetics, safety, and tolerability of lumacaftor in combination with ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the F508del-mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A Cohort 1: Participants aged 6 through 8 years will receive LUM 200 milligram (mg) in fixed-dose combination with IVA 250 mg orally every 12 hours (q12h) for 14 days. Part A Cohort 2: Participants aged 9 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 14 days. Part B: Participants aged 6 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 24 weeks.
Drug: Lumacaftor · Drug: Ivacaftor
Also known as: VX-809
Also known as: VX-770
Part A: Observed Plasma Concentration of Lumacaftor (LUM) and Ivacaftor (IVA) at Hour 4 Post-dose (C4h) on Day 1
Time frame: 4 hours post-morning dose on Day 1
Part A: Observed Plasma Concentration of Lumacaftor (LUM) and Ivacaftor (IVA) at Hour 4 Post-dose (C4h) on Day 14
Time frame: 4 hours post-morning dose on Day 14
Part A: Area Under the Plasma Concentration-Time Curve From Time 0 to End of Dosing Interval (AUCtau) of Lumacaftor (LUM) and Ivacaftor (IVA)
The AUCtau is the area under the concentration versus time curve from time 0 to time tau, where tau is the time at the end of dosing interval.
Time frame: Day 14 (pre-morning dose, 4, 6, 12, and 24 hours post-morning dose for LUM; pre-morning dose, 2, 4, 6, 12 hours post-morning dose for IVA)
Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first study drug dose to Week 26 were considered treatment-emergent.
Time frame: Day 1 up to Week 26
Part A: Observed Plasma Concentration of Lumacaftor Metabolite (M28-LUM) and Ivacaftor Metabolites (M1-IVA and M6-IVA) at Hour 4 Post-dose (C4h) on Day 1 and 14
Time frame: Day 1, Day 14
Part A: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first study drug dose through the end of Part A were considered treatment-emergent.
Time frame: Day 1 up to Day 28
Part B: Average Absolute Change From Baseline in Sweat Chloride at Day 15 and at Week 4
Sweat samples were collected using an approved collection device. Baseline was defined as the average of the measurements at screening and on Day 1 pre-dose. Average of Day 15 and Week 4 measurements was taken and change was calculated as: Average (Day 15 and Week 4 measurement) minus Baseline measurement.
Time frame: Baseline, Day 15 and Week 4
Part B: Absolute Change in Sweat Chloride From Week 24 at Week 26
Sweat samples were collected using an approved collection device. Change = Week 26 minus Week 24.
Time frame: Week 24, Week 26
Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24
BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).
Time frame: Baseline, Week 24
Part B: Absolute Change From Baseline in BMI-for-age Z-score at Week 24
BMI was defined as weight in kg divided by height\*height in m\^2. z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from -infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score). The BMI-for-age z-scores were calculated using National Center for Health Statistics growth charts.
Time frame: Baseline, Week 24
Part B: Absolute Change From Baseline in Weight at Week 24
Time frame: Baseline, Week 24
Part B: Absolute Change From Baseline in Weight-for-age Z-score at Week 24
Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from -infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score (weight z-score). The weight-for-age z-scores were calculated using National Center for Health Statistics growth charts.
Time frame: Baseline, Week 24
Part B: Absolute Change From Baseline in Height at Week 24
Time frame: Baseline, Week 24
Part B: Absolute Change From Baseline in Height-for-age Z-score at Week 24
Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from -infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score (height z-score). The height-for-age z-scores were calculated using National Center for Health Statistics growth charts.
Time frame: Baseline, Week 24
Part B: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24
The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: Baseline, Week 24
Part B: Absolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domains at Week 24
The TSQM is a 14-item self-administered questionnaire which measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.
Time frame: Baseline, Week 24
Part B: Pre-dose Concentration (Ctrough) and 3 to 6 Hours Post-dose Concentration (C3-6hr) of Lumacaftor, Lumacaftor Metabolite (M28-LUM), Ivacaftor and Ivacaftor Metabolites (M1-IVA and M6-IVA)
Ctrough and C3-6hr for lumacaftor, M28 lumacaftor (lumacaftor metabolite), ivacaftor, M1 ivacaftor (ivacaftor metabolite), and M6 ivacaftor (ivacaftor metabolite) were calculated. Ctrough was observed pre-dose concentration. C3-6hr was observed concentration at 3 to 6 hours post- dose.
Time frame: For Ctrough: pre-morning dose on Week 4, Week 6 and Week 24; For C3-6hr: 3 to 6 hours post-morning dose on Day 1, 15 and Week 4
| Milestone | Lumacaftor/Ivacaftor (LUM/IVA) |
|---|---|
| Started | 10 |
| Part a cohort 1 (6 to 8 years) | 5 |
| Part a cohort 2 (9 to 11 years) | 5 |
| Completed | 10 |
| Not completed | 0 |
| Milestone | Lumacaftor/Ivacaftor (LUM/IVA) |
|---|---|
| Started | 58 |
| Completed | 54 |
| Not completed | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Physician decision | 1 |
| nanogram per milliliter (ng/mL) | Part A Overall Arm: LUM/IVA |
|---|---|
| LUM | 15200 ± 6740 |
| IVA | 1920 ± 727 |
| ng/mL | Part A Overall Arm: LUM/IVA |
|---|---|
| LUM | 24500 ± 10400 |
| IVA | 622 ± 322 |
The AUCtau is the area under the concentration versus time curve from time 0 to time tau, where tau is the time at the end of dosing interval.
| ng*hr/mL | Part A Overall Arm: LUM/IVA |
|---|---|
| LUM | 387600 (280700 to 640800) |
| IVA | 6838 (2689 to 12100) |
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first study drug dose to Week 26 were considered treatment-emergent.
| participants | Part B: LUM/IVA |
|---|---|
| AEs | 55 |
| SAEs | 4 |
| ng/mL | Part A Overall Arm: LUM/IVA |
|---|---|
| M28-LUM (Day 1) | 176 ± 79.0 |
| M1-IVA (Day 1) | 3940 ± 1380 |
| M6-IVA (Day 1) | 1810 ± 981 |
| M28-LUM (Day 14) | 2040 ± 1230 |
| M1-IVA (Day 14) | 2380 ± 1360 |
| M6-IVA (Day 14) | 4240 ± 1990 |
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first study drug dose through the end of Part A were considered treatment-emergent.
| participants | Part A Overall Arm: LUM/IVA |
|---|---|
| Part A Cohort 1: AEs (n=5) | 4 |
| Part A Cohort 1: SAEs (n=5) | 0 |
| Part A Cohort 2: AEs (n=5) | 3 |
| Part A Cohort 2: SAEs (n=5) | 0 |
Sweat samples were collected using an approved collection device. Baseline was defined as the average of the measurements at screening and on Day 1 pre-dose. Average of Day 15 and Week 4 measurements was taken and change was calculated as: Average (Day 15 and Week 4 measurement) minus Baseline measurement.
| millimole per liter (mmol/L) | Part B: LUM/IVA |
|---|---|
| Part B: Average Absolute Change From Baseline in Sweat Chloride at Day 15 and at Week 4 | -19.7 (-23.2 to -16.3) |
Sweat samples were collected using an approved collection device. Change = Week 26 minus Week 24.
| mmol/L | Part B: LUM/IVA |
|---|---|
| Part B: Absolute Change in Sweat Chloride From Week 24 at Week 26 | 21.3 (18.6 to 24.0) |
BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).
| kilogram per square meter (kg/m^2) | Part B: LUM/IVA |
|---|---|
| Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24 | 0.64 (0.46 to 0.83) |
BMI was defined as weight in kg divided by height\*height in m\^2. z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from -infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score). The BMI-for-age z-scores were calculated using National Center for Health Statistics growth charts.
| z-score | Part B: LUM/IVA |
|---|---|
| Part B: Absolute Change From Baseline in BMI-for-age Z-score at Week 24 | 0.15 (0.08 to 0.22) |
| kilograms (kg) | Part B: LUM/IVA |
|---|---|
| Part B: Absolute Change From Baseline in Weight at Week 24 | 2.6 (2.2 to 3.0) |
Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from -infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score (weight z-score). The weight-for-age z-scores were calculated using National Center for Health Statistics growth charts.
| z-score | Part B: LUM/IVA |
|---|---|
| Part B: Absolute Change From Baseline in Weight-for-age Z-score at Week 24 | 0.13 (0.07 to 0.19) |
| centimeter (cm) | Part B: LUM/IVA |
|---|---|
| Part B: Absolute Change From Baseline in Height at Week 24 | 2.9 (2.6 to 3.2) |
Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from -infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score (height z-score). The height-for-age z-scores were calculated using National Center for Health Statistics growth charts.
| z-score | Part B: LUM/IVA |
|---|---|
| Part B: Absolute Change From Baseline in Height-for-age Z-score at Week 24 | 0.03 (-0.02 to 0.09) |
The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| Units on a scale | Part B: LUM/IVA |
|---|---|
| Part B: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24 | 5.4 (1.4 to 9.4) |
The TSQM is a 14-item self-administered questionnaire which measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.
| units on a scale | Part B: LUM/IVA |
|---|---|
| Change at Week 24: Effectiveness | 9.2 (4.3 to 14.1) |
| Change at Week 24: Side Effects | -0.3 (-1.4 to 0.8) |
| Change at Week 24: Convenience | 11.1 (7.1 to 15.1) |
| Change at Week 24: Global Score | 3.6 (-2.0 to 9.1) |
Ctrough and C3-6hr for lumacaftor, M28 lumacaftor (lumacaftor metabolite), ivacaftor, M1 ivacaftor (ivacaftor metabolite), and M6 ivacaftor (ivacaftor metabolite) were calculated. Ctrough was observed pre-dose concentration. C3-6hr was observed concentration at 3 to 6 hours post- dose.
| ng/mL | Part B: LUM/IVA |
|---|---|
| C3-6h LUM (Day 1) (n=57) | 17100 ± 6260 |
| C3-6h IVA (Day 1) (n=57) | 1980 ± 850 |
| C3-6h M28-LUM (Day 1) (n=57) | 186 ± 96.3 |
| C3-6h M1-IVA (Day 1) (n=57) | 4170 ± 1940 |
| C3-6h M6-IVA (Day 1) (n=57) | 2040 ± 1650 |
| C3-6h LUM (Day 15) (n=55) | 21400 ± 6850 |
| C3-6h IVA (Day 15) (n=55) | 751 ± 433 |
| C3-6h M28-LUM (Day 15) (n=55) | 1660 ± 843 |
| C3-6h M1-IVA (Day 15) (n=55) | 2670 ± 1330 |
| C3-6h M6-IVA (Day 15) (n=55) | 4360 ± 2340 |
| C3-6h LUM (Week 4) (n=54) | 22000 ± 8470 |
| C3-6h IVA (Week 4) (n=54) | 779 ± 389 |
| C3-6h M28-LUM (Week 4) (n=54) | 1730 ± 884 |
| C3-6h M1-IVA (Week 4) (n=54) | 2800 ± 1410 |
| C3-6h M6-IVA (Week 4) (n=54) | 4690 ± 3360 |
| Ctrough LUM (Week 4) (n=53) | 12300 ± 6780 |
| Ctrough IVA (Week 4) (n=53) | 171 ± 228 |
| Ctrough M28-LUM (Week 4) (n=53) | 1780 ± 903 |
| Ctrough M1-IVA (Week 4) (n=53) | 684 ± 816 |
| Ctrough M6-IVA (Week 4) (n=53) | 2490 ± 2150 |
| Ctrough LUM (Week 16) (n=53) | 11500 ± 6020 |
| Ctrough IVA (Week 16) (n=52) | 153 ± 150 |
| Ctrough M28-LUM (Week 16) (n=53) | 1610 ± 859 |
| Ctrough M1-IVA (Week 16) (n=53) | 690 ± 627 |
| Ctrough M6-IVA (Week 16) (n=53) | 2360 ± 1570 |
| Ctrough LUM (Week 24) (n=51) | 11400 ± 5300 |
| Ctrough IVA (Week 24) (n=51) | 118 ± 87.2 |
| Ctrough M28-LUM (Week 24) (n=51) | 1710 ± 947 |
| Ctrough M1-IVA (Week 24) (n=51) | 493 ± 409 |
| Ctrough M6-IVA (Week 24) (n=51) | 1790 ± 1180 |
Collected over Part A: Day 1 up to Day 28; Part B: Day 1 up to Week 26. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Cohort 1: LUM/IVA | — | 0/5 (0%) | 4/5 (80%) |
| Part A Cohort 2: LUM/IVA | — | 0/5 (0%) | 3/5 (60%) |
| Part B: LUM/IVA | — | 4/58 (6.9%) | 55/58 (94.8%) |
| Event | Part A Cohort 1: LUM/IVA | Part A Cohort 2: LUM/IVA | Part B: LUM/IVA |
|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/5 | 0/5 | 2/58 |
| IleusGastrointestinal disorders | 0/5 | 0/5 | 1/58 |
| Alanine aminotransferase increasedInvestigations | 0/5 | 0/5 | 1/58 |
| Aspartate aminotransferase increasedInvestigations | 0/5 | 0/5 | 1/58 |
| Event | Part A Cohort 1: LUM/IVA | Part A Cohort 2: LUM/IVA | Part B: LUM/IVA |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 1/5 | 3/5 | 29/58 |
| HeadacheNervous system disorders | 2/5 | 1/5 | 12/58 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 0/5 | 1/5 | 12/58 |
| Abdominal pain upperGastrointestinal disorders | 1/5 | 0/5 | 8/58 |
| ConstipationGastrointestinal disorders | 1/5 | 0/5 | 5/58 |
| DiarrhoeaGastrointestinal disorders | 1/5 | 0/5 | 4/58 |
| Forced Expiratory Volume DecreasedInvestigations | 0/5 | 1/5 | 0/58 |
| Hepatic Enzyme IncreasedInvestigations | 1/5 | 0/5 | 0/58 |
| LymphadenopathyBlood and lymphatic system disorders | 1/5 | 0/5 | 1/58 |
| PyrexiaGeneral disorders | 1/5 | 0/5 | 6/58 |
The Safety Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Lumacaftor/Ivacaftor (LUM/IVA) |
|---|---|
| Part A Cohort 1 (n=5) | 6.6 ± 0.89 |
| Part A Cohort 2 (n=5) | 9.6 ± 0.89 |
| Part B (n=58) | 9.1 ± 1.53 |
| Sex/Gender, Customized(participants) | Lumacaftor/Ivacaftor (LUM/IVA) |
|---|---|
| Part A Cohort 1 (n=5): Female | 1 |
| Part A Cohort 1 (n=5): Male | 4 |
| Part A Cohort 2 (n=5): Female | 1 |
| Part A Cohort 2 (n=5): Male | 4 |
| Part B (n=58): Female | 31 |
| Part B (n=58): Male | 27 |
The record gives a start of Jul 2013, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumacaftor
Vertex Pharmaceuticals Incorporated →